Techsomed Expands AI-Powered BioTraceIO360 Platform to Kidney Ablation Following FDA 510(k) Clearance
核心洞察
Techsomed (搜索) received FDA 510(k) clearance to expand its BioTraceIO360 (搜索) software platform for percutaneous ablation of soft tissue (搜索) in the kidney, adding to its previously cleared liver application.
The AI-driven image-guided therapy platform enables physicians to plan and simulate ablation zones pre-procedure, guide procedures with quantitative feedback, and verify coverage for consistent outcomes.
This milestone advances Techsomed (搜索)'s vision for a unified multi-organ, hardware-agnostic platform that standardizes minimally invasive care from planning through verification.
Techsomed (搜索) announced that the U.S. FDA has granted 510(k) clearance expanding indications for its BioTraceIO360 (搜索) software platform to include percutaneous ablation of soft tissue (搜索) in the kidney, building upon its previously cleared liver application. The milestone represents a significant step toward the company's vision of creating a multi-organ, hardware-agnostic image-guided therapy platform that standardizes minimally invasive care from planning through verification.
The clearance addresses a substantial clinical need, as kidney cancer (搜索) affects roughly 82,000 people in the United States each year. For carefully selected patients, minimally invasive, image-guided ablation offers a nephron-sparing alternative to surgery that is gaining adoption among interventional teams.
Platform Capabilities and Clinical Impact
The BioTraceIO360 (搜索) platform enables surgeons to plan and simulate ablation zones pre-procedure, guide and adapt during procedures with quantitative feedback, and verify and document coverage to support consistent outcomes. This comprehensive approach aims to enhance precision and reproducibility in interventional oncology procedures.
"We're encouraged by Techsomed (搜索)'s new FDA clearance and look forward to expanding our use of its AI-driven image-guided therapy platform," said Dr. Eric Hoffer, Associate Professor of Radiology at Dartmouth Hitchcock Medical Center. "Our interventional radiologists are already seeing value from BioTrace, and this milestone creates even more opportunity to enhance patient care."
Technical Foundation and Previous Validation
The BioTraceIO360 (搜索) platform previously received de novo clearance in January 2024 as a liver ablation software designed for tissue response prediction. The initial clearance was supported by data from a multicenter pivotal trial (NCT04970212) involving 50 patients enrolled through clinical trial sites in the US.
In the pivotal study, the BioTraceIO360 (搜索) software demonstrated superiority to immediate post-procedure contrast-enhanced CT (CECT) scans in estimating the ablation zone at the time of 24-hour CECT, when maximum ablation zone expansion is observed. The software accurately predicted the ablation zone as visualized 24 hours post-procedure, providing information about size and shape based solely on ultrasound imaging that correlates with CT information.
Strategic Vision for Multi-Organ Platform
"This clearance is a pivotal step toward making interventional oncology a precise, reproducible science," said Yossi Abu, CEO of TechsoMed (搜索). "Extending BioTraceIO360 (搜索) from liver to kidney lays the foundation for a unified multi-organ platform that gives physicians greater precision, consistency, and confidence."
The BioTraceIO platform is designed to integrate with Techsomed (搜索)'s VisAbleIO (搜索) platform, an AI-powered product for treatment planning and confirmation for thermal ablation therapy. This integration supports the company's broader strategy of creating comprehensive solutions for image-guided interventional procedures.
Availability and Market Access
BioTraceIO360 (搜索) is now available in the U.S. for both liver and kidney ablation workflows. The platform comprises the BioTraceIO Vision and BioTraceIO Precision software products, both of which have received FDA clearance for marketing in the United States.
Founded in 2015, Techsomed (搜索) operates as an image-guided therapy software company with locations in Israel, Germany, and Japan, focusing on AI-powered, hardware-agnostic solutions that unify planning, execution, and verification for minimally invasive procedures.